Long-COVID
12
4
5
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 12 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (12)
ASAP - Assisted Immediate Augmented Post-/Long-COVID Plan for Patients Infected With COVID-19
Effect of Daily Walnut Consumption on Memory in Subjects With Long-COVID
Long-term COVID and Rehabilitation
Pursuing Reduction in Fatigue After COVID-19 Via Exercise and Rehabilitation (PREFACER): A Randomized Feasibility Trial
Symptom-based Rehabilitation Compared to Usual Care in Post-COVID - a Randomized Controlled Trial
Osteopathic Manipulative Therapy Effects on Post-Acute Sequelae of COVID-19 (PASC) or Long COVID
Low Dose Rapamycin in ME/CFS, Long-COVID, and Other Infection Associated Chronic Conditions
Skeletal Muscle in PASC and ME/CFS Patients
Effectiveness of Non-invasive Neuromodulation in Patients With Long-COVID
Sulfureous Water Therapy in Viral Respiratory Diseases
Sociodemographic, Clinical, Quality of Life and Health Care Conditions in COVID-19 Survivors.
Early and Late Complications of COVID-19